Cargando…
Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Epidermal growth factor receptor (EGFR) inhibitors are widely used in the treatment of cancer. EGFR-targeted treatment is known to be associated with a high incidence of dermatological adverse reactions, including papulopustular rash, which can be dose-limiting and may affect compliance to treatment...
Autores principales: | Bangsgaard, Nannie, Houtkamp, Mischa, Schuurhuis, Danita H., Parren, Paul W. H. I., Baadsgaard, Ole, Niessen, Hans W. M., Skov, Lone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382563/ https://www.ncbi.nlm.nih.gov/pubmed/22761877 http://dx.doi.org/10.1371/journal.pone.0039706 |
Ejemplares similares
-
Systematic study of tissue factor expression in solid tumors
por: de Bono, Johann S., et al.
Publicado: (2022) -
The role of epidermal sphingolipids in dermatologic diseases
por: Borodzicz, Sonia, et al.
Publicado: (2016) -
The use of epidermal growth factor in dermatological practice
por: Shin, Sun Hye, et al.
Publicado: (2022) -
Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012) -
Epidermal bulla: A dermatology complication of radial artery compression band
por: Vasu, Nandhakumar, et al.
Publicado: (2018)